Alaunos Therapeutics Bolsa (NASDAQ: TCRT)

Últimas noticias sobre Alaunos Therapeutics (NASDAQ:TCRT) Bolsa

Alaunos Therapeutics

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics Inc

<p><strong>Astera Labs Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares are up 23.4% to $89.54 in November following the company's <a href="https://www.benzinga.com/news/earnings/24/11/41754359/astera-labs-stock-is-ripping-higher-today-whats-going-on">impressive third-quarter earnings</a> beat Wall Street expectations, reinforcing its role as a critical player in AI infrastructure. </p>
<p><strong>What To Know:</strong> Astera reported earnings of 23 cents per share, exceeding the estimated 17 cents, alongside revenue of $113.1 million, up 206% year-over-year and well above analyst forecasts of $97.4 million. </p>
<p><strong>CEO</strong> <strong>Jitendra Mohan</strong> highlighted that the company achieved its fifth consecutive quarter of record-breaking revenue, with sales rising 47% from the previous quarter, driven by new growth in AI connectivity solutions.</p>
<p>Astera's latest product, the <strong>Scorpio Smart Fabric Switch</strong>, is central to its strategy. These switches are designed to enhance data transfer speeds between GPUs, CPUs and storage devices, addressing critical needs in AI data centers where performance demands are skyrocketing.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a></strong></p>
<p><strong>What Else:</strong> The company's strong performance and promising product pipeline prompted multiple analysts to raise their price targets.</p>
<p><strong>JPMorgan</strong> increased its target to $110 per share, while <strong>Deutsche Bank</strong>, <strong>Barclays</strong> and others <a href="https://www.benzinga.com/quote/ALAB/analyst-ratings">made upward revisions</a>. </p>
<p>Astera's revenue forecast for the fourth quarter of $126–$130 million, alongside expected earnings of 25 cents to 26 cents per share, has added momentum to investor enthusiasm.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a></strong></p>
<h2 class="wp-block-heading">How To Buy ALAB Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Astera Labs&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ALAB has a 52-week high of $100.09 and a 52-week low of $36.22.</p>


News

ALAB

Astera Labs (ALAB) Stock Is Up 23% This Month: What's Going On?

<p><strong>CV Sciences, Inc.</strong> (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTCQB">CVSI</a>), a <a href="http://benzinga.com/topic/hemp">hemp</a>-focused wellness company, announced <strong>stable revenue in its Q3 2024 financials</strong> on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year.</p>
<h4 class="wp-block-heading"><strong>Q3 2024 Financial Highlights</strong></h4>
<ul>
<li><strong>Revenue:</strong> $3.9 million, a 5% decline from $4.1 million in Q3 2023 and stable compared to <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">$4 million in Q2 2024</a>.</li>
<li><strong>Net loss:</strong> $456,000, slightly higher than the $447,000 loss in Q3 2023.</li>
<li><strong>Adjusted EBITDA:</strong> Loss of $75,000, significantly improved from a loss of $361,000 in Q3 2023.</li>
<li><strong>Gross profit:</strong> $1.78 million, a slight decrease from $1.84 million in Q3 2023, reflecting an improved gross margin of 46%, up from 45.1% in the same period last year.</li>
</ul>
<h3 class="wp-block-heading"><strong>New Product Lines Boost Growth</strong></h3>
<p>Operating with a cash balance of $1 million, CV Sciences recorded an adjusted EBITDA loss of $75,000, <a href="https://www.benzinga.com/markets/cannabis/24/03/37988133/hemp-focused-wellness-co-moves-closer-to-profitability-reports-flat-2023-revenue-increase-in-gro">inching closer</a> to cash flow break-even.</p>
<p>Furthermore, the company's recent launches, including the cannabinoid-free +PlusHLTH supplement line, target cognitive health, stress relief and metabolism support. Additionally, CV Sciences expanded its pet health segment with hip, joint and calming chews, aiming to capture a broader consumer base.</p>
<ul>
<li><strong><em>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter </em></strong><a href="https://newsletteremail.benzinga.com/subscribe"><strong><em>here</em></strong></a><strong><em>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</em></strong></li>
</ul>
<h3 class="wp-block-heading"><strong>Management Commentary</strong></h3>
<p>CEO <strong>Joseph Dowling</strong> highlighted the <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">steady core revenue</a> in a challenging environment, noting new products and acquisitions as positioning factors for growth in 2025. &#8220;Our third quarter 2024 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow,&#8221; Dowling <a href="https://www.prnewswire.com/news-releases/cv-sciences-inc-reports-third-quarter-2024-financial-results-302305079.html">said</a> in a press release.</p>
<p><strong>Read Also: </strong><a href="https://www.benzinga.com/24/11/41971875/cbd-pioneer-charlottes-web-narrows-loss-in-q3-focuses-on-long-term-growth-amid-challenging-cannabis-industry-environment"><strong>CBD Pioneer Charlotte&#8217;s Web Narrows Loss In Q3, Focuses On Long-Term Growth</strong></a></p>
<p>"We look forward to organically grow our business and pursue additional M&amp;A opportunities in the near future to improve our top-line revenue, profitability and shareholder value," he added.</p>
<h3 class="wp-block-heading"><strong>CV Sciences Holds Top Market Spot</strong></h3>
<p>In Q3, CV Sciences further solidified its market position, maintaining top-seller status in the natural products retail channel, according to SPINS data. The company also secured $0.9 million in financing from <strong>Streeterville</strong>, aimed at fueling operational and product expansion.</p>
<p><strong>CVSI Price Action</strong><br />CVSI's shares were trading 7.73% lower at $0.04235 per share at the time of this writing around 12:35 PM ET Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41974843/cbd-pharma-co-medipharm-37-increase-in-q3-international-sales-15-yoy-revenue-growth"><strong>CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth</strong></a></li>
</ul>


Cannabis

Earnings

CVSI

CV Sciences Q3: Revenue Stable Amid New Launches, Financing

Trading Ideas

RIVN

iShares Trust Barclays 20+ Year Treasury Bond Fund

Soros Fund Management 13F Shows Exited Position In SPDR S&P 500 ETF, Previously Holding 450,000 Shares; Exited Stake In Rivian Automotive Call Options, Previously Holding 5,450,000 Shares; Exited Put Position In Ishares 20+ Year Treasury Bond ETF, Previously Holding 360,000 Shares; Exited Stake In Westrock Co, Previously Holding 3,342,953 Shares;  Exited Stake In Livongo Health Convertible Notes, Previously Holding $45M In Principal

PMNT

Perfect Moment Q2 EPS $(0.17) Up From $(0.29) YoY; Revenue $3.833M Down From $5.888M YoY

<p>Canaccord Genuity  analyst Joseph Vafi   maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and raises the price target from $22 to $32.</p>


Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Hut 8, Raises Price Target to $32

<p><a href="https://truthsocial.com/@realDonaldTrump/113483513301208163" title="https://truthsocial.com/@realDonaldTrump/113483513301208163">https://truthsocial.com/@realDonaldTrump/113483513301208163</a></p>


Macro Notification

Politics

General

Trump Picks Jay Clayton For Chairman Of U.S. Securities And Exchange Commission

PXLW

Pixelworks Enters $10M "At-The-Market" Equity Offering Agreement With Roth Capital, Allowing Periodic Common Stock Sales With 2.5% Commission; Roth To Act As Sales Agent

GOOGL

LBRDA

Soros Fund Management 13F Shows Decreased Stake In Rivian Automotive Convertible Notes By 21% To $155.9M In Principal; Decreased Stake In Wayfair Convertible Notes By 11% To $119.5M In Principal; Decreased Stake In Liberty Broadband Corp By 19% To 1,119,893 Shares; Decreased Stake In Alphabet Class A By 43% To 517,890 Shares; Decreased Put Position In Ishares IBoxx High Yield Corporate Bond ETF By 40% To 1,500,000 Shares

Discover Financial Reports $100.7B In Credit Card Loans As Of October 2024, Up From $98.7B YoY; Average Balances Remain Stable At $100.2B; Net Principal Charge-Off Rate Drops To 4.31% With Disaster Relief Impact, Though Up From 4.42% YoY; Delinquency Rate Rises Slightly To 3.87%

Management

Zillow Group Appoints Jun Choo As COO

Offerings

GYRE

Gyre Therapeutics Files For Up To $150M Mixed Shelf

WIIM

IZEA

IZEA Worldwide shares are trading lower after the company reported worse-than-expected Q3 financial results.

<p>BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.58) by 32.76 percent.</p>


Earnings Beats

BKYI

BIO-key Intl Q3 2024 Adj EPS $(0.39) Beats $(0.58) Estimate

TFFP

TFF Pharmaceutical shares are trading lower after the company announced it will wind down its operations.

<p>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.52) by 53.85 percent.</p>


ENVB

Enveric Biosciences Q3 2024 GAAP EPS $(0.24) Beats $(0.52) Estimate

AKYA

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

DOCN

OKTA

Soros Fund Management 13F Shows Increased Put Position In SPDR S&P 500 ETF By 608% To 2,123,000 Shares; Increased Stake In Ishares Financial Select Sector SPDR ETF By 22,720% To 2,800,000 Shares; Increased Stake In JD.com By 114% To 2,730,000 Shares; Increased Stake In Okta Convertible Notes By 75% To $79.1M In Principal; Increased Stake In DigitalOcean Convertible Notes By 302% To $116.5M In Principal

Buybacks

Primerica Board Authorizes $450M Share Repurchase Program To Occur Through December 31, 2025

XPON

Expion360 shares are trading lower after the company reported a year-over-year decline in Q3 revenue results.

Asset Sales

BLFS

BioLife Solutions Sells Subsidiary, Arctic Solutions, For $6.1M

The market has been high on Alaunos Therapeutics Inc (TCRT)  stock recently. TCRT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Alaunos Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TCRT!See Full TCRT ReportWhat is Stock Senti

Is Alaunos Therapeutics Inc (TCRT) a Stock to Watch After Losing -8.86% This Week?

Alaunos Therapeutics (TCRT) has released an update. Alaunos Therapeutics, Inc. has successfully regained compliance with Nasdaq's minimum $1.00 bid...

Alaunos Therapeutics Regains Nasdaq Listing Compliance

Alaunos Therapeutics (TCRT) has released an update. Michael Wong resigned as Vice President, Finance of Alaunos Therapeutics, and Ferdinand Groenew...

Alaunos Therapeutics Announces Executive Financial Leadership Changes

Wall Street is positive on Alaunos Therapeutics Inc (TCRT). On average, analysts give Alaunos Therapeutics Inc a Hold rating. The average price target is $2.998, which means analysts expect the stock to climb by 74.30% over the next twelve months.That average ranking earns Alaunos Therapeutics Inc an Analyst Rating of 5, w

How Does Alaunos Therapeutics Inc (TCRT) Stock Rank on Wall Street Friday?

Overall market sentiment has been high on Alaunos Therapeutics Inc (TCRT)  stock lately. TCRT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Alaunos Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TCRT!See Full TCRT ReportWh

Do Traders Think Alaunos Therapeutics Inc (TCRT) Can Keep Climbing Tuesday?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Alaunos Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/"><strong>TCRT</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Alaunos Therapeutics reported earnings per share of -55 cents. This was below the analyst estimate for EPS of -45 cents.</li><li>The company reported revenue of $1,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/tcrt-stock-earnings-alaunos-therapeutics-for-q4-of-2023/">TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Alaunos Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/"><strong>TCRT</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Alaunos Therapeutics reported earnings per share of -11 cents.</li><li>The company reported revenue of $1,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/tcrt-stock-earnings-alaunos-therapeutics-for-q1-of-2024/">TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Alaunos Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/"><strong>TCRT</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Alaunos Therapeutics reported earnings per share of -71 cents.</li><li>The company reported revenue of $4,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/tcrt-stock-earnings-alaunos-therapeutics-for-q2-of-2024/">TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024

The latest announcement is out from Alaunos Therapeutics ( ($TCRT) ). Alaunos Therapeutics, Inc. has decided to terminate its amended licensing agr...

Comments

Alaunos Therapeutics

Noticias

Últimas noticias sobre Alaunos Therapeutics (NASDAQ:TCRT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL